Article Text

Download PDFPDF
Synchronous Primary Cancers of the Endometrium and Ovary With the Same Histopathologic Type Versus Endometrial Cancer With Ovarian Metastasis: A Single Institution Review of 72 Cases
  1. Tugan Bese, MD*,
  2. Veysel Sal, MD*,
  3. Ilker Kahramanoglu, MD*,
  4. Nedim Tokgozoglu, MD*,
  5. Fuat Demirkiran, MD*,
  6. Hasan Turan, MD*,
  7. Sennur Ilvan, MD and
  8. Macit Arvas, MD*
  1. *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and
  2. Department of Pathology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey.
  1. Address correspondence and reprint requests to Veysel Sal, MD, Istanbul University Cerrahpasa Medical Faculty, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Kocamustafapasa Cad. No:53, Fatih- Istanbul, Turkey, 34098. E-mail:


Objective The purpose of this study was to evaluate the clinicopathological characteristics and survival outcomes of women with simultaneous endometrial and ovarian carcinomas having the same histopathologic type.

Materials and Methods A review of medical records from 1997 to 2015 identified 72 patients with simultaneous carcinomas of the endometrium and ovary with the same histopathologic type. Patients with synchronous primary cancers of endometrium and ovary (SCEOs) were compared with patients with primary endometrial cancer with ovarian metastasis (ECOM). Clinical and pathological data were obtained from the patients’ medical records. Clinicopathological variables including categorical data were analyzed by χ2 or Fisher exact test and continuous data by a Student t test. A Kaplan-Meier survival analysis was performed and compared by using the log-rank test.

Results A univariate and multivariate analysis of 72 patients with SCEO with the same histopathologic type revealed that SCEO is an independent prognostic factor of 10-year overall survival. There were 31 patients in the SCEO group and 41 patients in the ECOM group. With a mean follow-up time of 68.2 months, the 10-year overall survival rates were 61.3% and 36.6% in SCEO and ECOM groups, respectively (P = 0.029). Age, menopausal status, stage of ovarian cancer, performing lymphadenectomy, grade of endometrial tumor, omental metastasis, and residual tumor were found to be significant risk factors for recurrence in the synchronous group.

Conclusions The differentiation between SCEO and ECOM is of great clinical importance while our results showed a better prognosis for patients with SCEO compared with patients with ECOM. More aggressive therapeutic approaches may be considered for patients with SCEO who are older, postmenopausal, and/or have advanced grade of endometrial tumor, omental metastasis, and residual tumor. Lymphadenectomy should be performed in every patient with SCEO.

  • Endometrial cancer
  • Ovarian cancer
  • Synchronous primary cancers
  • Prognosis
  • Metastatic cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.